Best Life Sciences Companies in Cardiff, United Kingdom
The 33 best Life Sciences companies in Cardiff, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Draigtherapeutics.
Our analysis of 62 Life Sciences companies
$9.8b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2026.
Ranked: Best Life Sciences companies in Cardiff
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Draigtherapeutics Developer of targeted neuromodulators for neuropsychiatric disorders treatment 35Funding top 25%Moat top 35%Talent top 38%Global top 45% All 6 signals ▾Fundingtop 25% Moattop 35% Talenttop 38% Globaltop 45% Techbottom 36% Marketbottom 31% Funding: Raised $140M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) Moat: Soonicorn · 5 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 35/100 | $140M | 16 mo ago | Series A | Simon Ward Co-Founder | 2021 | WordPressApple iCloud MailMicrosoft 365+14 | — | — |
| 2 | Alesi Surgical Developer of surgical smoke elimination systems for open and laparoscopic procedures 21Product top 32%Funding top 35%Patents top 36%Innovation top 37% All 10 signals ▾Producttop 32% Fundingtop 35% Patentstop 36% Innovationtop 37% Techtop 45% Moattop 45% Globalbottom 42% Growthbottom 38% Marketbottom 18% Fin. healthbottom 13% Product: 4 distinct product lines · 1 published app (300 installs) Funding: Raised $27.7M across 8 rounds · 8 rounds over 16 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $28M | 6 mo ago | Series C | — | 2009 | WordPressMySQLPHP+24 | 81 patents Patents concentrated in health & consumer products | — |
| 3 | Q Chip Drug delivery company delivering a tuneable sustained release technology platform for peptide and… | $14M | 185 mo ago | Acquired | — | 2003 | — | 64 patents Solid bead generation, collection, and separation technologies for microbead production | — |
| 4 | Antiverse Developer of computational platform for de novo design of antibody therapeutics 48AI top 30%Tech top 32%Talent top 34%Funding top 39% All 8 signals ▾AItop 30% Techtop 32% Talenttop 34% Fundingtop 39% Moattop 48% Newsbottom 41% Globalbottom 39% Marketbottom 22% AI: Classified as an AI company · Product described with: machine learning Tech: 35 technologies across 5/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 48/100 | $10M | 8 mo ago | Series A | Murat Tunaboylu Co-Founder & CEO | 2017 | WebflowApple iCloud MailGoogle Workspace+19 | — | — |
| 5 | Diurnal Developer of hormone therapeutics for the treatment of rare and chronic endocrine diseases | $10M | 72 mo ago | Acquired | — | 2004 | — | 125 patents Hormone drug formulations and delivery systems, focusing on testosterone and hydrocortisone. | — |
| 6 | Intelligent Ultrasound Ultrasound imaging analytics platform for improving image quality and operational efficency | $10M | 78 mo ago | Acquired | Stuart Gall CEO | 2004 | WordPress Block EditorElementorCart Functionality+22 | 27 patents Real-time 3D/4D ultrasound imaging and fetal assessment automation | — |
| 7 | MyHealthChecked Provider of an online platform to order diagnostic test kits sample collection swab for Covid-19 detection | $8M | 90 mo ago | Public | Penny Mccormick CEO | 2008 | SanitySentryZendesk+23 | — | — |
| 8 | Biodexa Pharmaceuticals Developer of therapeutics for the treatment of brain cancer | $7M | 34 mo ago | Series A | Stephen Stamp CEO | 2000 | WordPressMySQLPHP+14 | — | — |
| 9 | Momentum Bioscience Developer of diagnostic solutions for the detection of infectious diseases | $6M | 61 mo ago | Series A | — | 2008 | — | 67 patents Microbial detection, separation, and enumeration using microfluidic and optical biosensor technologies | — |
| 10 | Nanotether Specialty company that offers technology for accelerating the progression of potential drug candidates | $4M | 170 mo ago | Acquired | — | 2012 | — | — | — |
| 11 | Celixir Stem Cell and Regenerative therapy for heart disease | $3M | 104 mo ago | Seed | — | 2009 | — | — | — |
| 12 | Glyconics Provider of spectroscopy-based diagnostic tool for respiratory disorders | $2M | 59 mo ago | Seed | — | 2013 | — | — | — |
| 13 | TrakCel Provider of a supply chain, traceability, a chain of identity and risk management software | $1M | 68 mo ago | Series A | Ravi Nalliah Co-Founder | 2012 | WordPress Block EditorWordPressMySQL+19 | 11 patents Biomedical sample condition monitoring and tracking systems for physiological/medicinal specimens | — |
| 14 | Mariposa Therapeutics Developer of novel treatments for keratin-related skin disorders | $1M | 7 mo ago | Seed | Thomas Hafner Co-Founder | 2019 | — | — | — |
| 15 | Trecento Diagnostics Developer of molecular assay based testing products for human and companion animal diagnostics | $387K | 81 mo ago | Seed | Mark Pinder CEO | 2014 | — | 6 patents Automated collection devices for plant and soil analytical sampling in agriculture | — |
| 16 | MeOmics Provider of neural biomarker discovery platform for psychiatric disorders | $185K | 8 mo ago | Seed | Jeremy Hall Co-Founder | 2021 | — | — | — |
| 17 | Genesis Biosciences Develops microbial and antimicrobial products using fermentation technology | $150K | 145 mo ago | Funding Raised | — | 2002 | WordPressMySQLPHP+14 | — | — |
Top 12 Life Sciences companies in Cardiff
#1
Series C · Cardiff, Wales · founded 2009 · 7 employees$27.7Mraised▾
Developer of surgical smoke elimination systems for open and laparoscopic procedures. The company's technology uses electrostatic precipitation to eliminate surgical smoke at its source. This provides advanced visualization, bioaerosol control, and stable pneumoperitoneum. The systems minimize workflow disruptions and patient carbon dioxide exposure during surgery.
- Apr 2026Series C$9.5M
- Sep 2024Series B$6.6M
- May 2017Series B$6.7M
- Mar 2015Series A$3.1M
#2
Series A · Cardiff, Wales · founded 2017 · 7 employees$10.1Mraised▾
Developer of computational platform for de novo design of antibody therapeutics. The platform combines machine learning techniques and cell line engineering for challenging targets. It facilitates design for drug targets, including G-protein coupled receptors and ion channels. The technology enables movement from target identification to functional antibody.
- Mar 2026Series A$9.3M
- Oct 2024Seed$4.6M
- Mar 2023Seed$3M
- Mar 2021Seed$1.9M
#3
Series A · Cardiff, Wales · founded 2021$140Mraised▾
Developer of targeted neuromodulators for neuropsychiatric disorders treatment. The company focuses on clinically validated mechanisms underlying prevalent and debilitating neuropsychiatric disorders. It aims to restore synaptic balance and deliver therapeutic benefits for patients. The company is advancing receptor modulators towards clinical development.
- Jun 2025Series A$140M
- 2024Seed—
#4
Seed · Cardiff, Wales · founded 2019 · 5 employees$1Mraised▾
Developer of novel treatments for keratin-related skin disorders. It focuses on developing innovative solutions to treat these conditions. The company leverages specialist expertise in epithelial cell biology and keratin intermediate filaments to create its treatments. Collaboration is a key aspect of its approach, seeking partnerships to advance research and bring new therapies to patients lacking current cures.
- Mar 2026Seed$1M
#5
Seed · Cardiff, Wales · founded 2021 · 6 employees$184.9Kraised▾
Provider of neural biomarker discovery platform for psychiatric disorders. The company advances in genetics and stem cell technology, combining genomics, phenomics, and cellomics to create a unique precision psychiatry platform for the treatment of psychiatric conditions, such as schizophrenia, bi-polar and other mental disorders.
- Feb 2026Seed$170.8K
- Feb 2026Grant (prize money)$34.2K
- Dec 2025Seed$414.3K
- 2025Seed$376K
#6
Series A · Cardiff, Wales · founded 2000 · 26 employees$6.8Mraised▾
Developer of therapeutics for the treatment of brain cancer. It offers a lead candidate, MTX110 a solubilised formulation of the histone deacetylase inhibitor, panobinostat used in aggressive rare/orphan brain cancer indications which includes recurrent glioblastoma, medulloblastoma and paediatric diffuse midline glioma.
- Dec 2023Series A$6.8M
#7
Acquired · Cardiff, Wales · founded 2004 · 36 employees$10.1Mraised▾
Developer of hormone therapeutics for the treatment of rare and chronic endocrine diseases. The lead product Alkindi is an immediate-release hydrocortisone preparation for pediatric patients with adrenal insufficiency. Other products include Ditest for hypogonadism, T3 modified release for hypothyroidism, Chronocort for congenital adrenal hyperplasia and adrenal insufficiency,
- Oct 2020Post IPO$10.4M
- Mar 2020Post IPO$14.6M
- Feb 2018Post IPO$15.3M
- Aug 2014Series A$10.1M
#8
Acquired · Cardiff, Wales · founded 2004 · 7 employees$9.8Mraised▾
Ultrasound imaging analytics platform for improving image quality and operational efficency. The company specializes in advanced ultrasound simulation and AI-driven imaging solutions for medical training and diagnostics. The company has been acquired by Surgical Science, enhancing its offerings in high-fidelity simulators like BodyWorks and HeartWorks for clinical education.
- Apr 2020Post IPO$5.2M
- Aug 2019Post IPO$7.6M
- Nov 2017Grant (prize money)$615.7K
- Oct 2017Post IPO$7M
#9
Series A · Cardiff, Wales · founded 2008 · 13 employees$5.8Mraised▾
Developer of diagnostic solutions for the detection of infectious diseases. Its proprietary platform Enzymatic Template Generation & Amplification (ETGA) detects microbial infections by measuring nucleic acid modifying enzymes. The company's flagship product is Cognition is based on ETGA technology.
- Sep 2021Series A$5.4M
- Sep 2011Seed$355K
#10
Acquired · Cardiff, Wales · founded 2003 · 13 employees$14.2Mraised▾
Q Chip is a drug delivery company with expertise in the application of fluidic droplet systems (including microfluidic and piezo actuator-based platforms). Focus is on formulating monodisperse microspheres for the controlled release of therapeutics. The Q-Sphera Microsphere production platform was developed in response to the limitations of current microsphere manufacturing methods and delivers consistent, reproducible and highly efficient cGMP-compliant production of microspheres whilst providing control over release kinetics. Q Chip also administer, sustained release products in development for acromegaly (Q-Octreotide) and diabetes (Q-Exenatide) which offer long duration of action with defined release profiles. Acquired by Midatech Pharma in December, 2014.
- May 2011Series C$6M
- Sep 2010Series B$3M
#11
Public · Cardiff, Wales · founded 2008 · 21 employees$8Mraised▾
Provider of an online platform to order diagnostic test kits sample collection swab for Covid-19 detection. It allows users to buy a test kit pack with a nasal swab, tube, biohazard bag, and absorbent pad having the instructions for use. The users can collect their swab sample and can send it back to the nearest lab for testing. Users can also track results by using the tracking number provided by the care team.
- Apr 2019Post IPO$3M
- Aug 2018Post IPO$2.3M
- Nov 2017Post IPO$2.6M
#12
Seed · Cardiff, Wales · founded 2013 · 2 employees$2Mraised▾
Provider of spectroscopy-based diagnostic tool for respiratory disorders. The flagship technology is a handheld device that uses infrared spectroscopy to analyze sputum samples for specific biomarkers for targeting Chronic Obstructive Pulmonary Disease (COPD) and diabetes.
- Nov 2021Seed$2M
- Oct 2020Grant (prize money)$110.1K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Cardiff researches in biotechnology
- Cardiff University21
- Cardiff Metropolitan University1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.